Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

TIL
Instil Bio, Inc. Common Stock
stock NASDAQ

Market Open
Aug 6, 2026 10:44:50 AM EDT
7.21USD-1.233%(-0.09)1,157
6.14Bid   8.52Ask   2.38Spread
Pre-market
0.00USD-100.000%(-7.25)0
After-hours
Aug 4, 2026 4:00:30 PM EDT
7.25USD-3.333%(-0.25)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
10:38AM EST  52 Weeks High And Low Article   Benzinga
Nov 15, 2021
07:00AM EST  Instil Bio Announces Poster Presentations at the 2021 Society for   GlobeNewswire Inc
07:00AM EST  -- Patients enrolled and recruitment ongoing in Phase 2 trial of ITIL-168 in melanoma (DELTA-1) -- Fast Track Designation granted by FDA for ITIL-168 in metastatic melanoma -- CoStAR mechanism of action data presented at SITC 2021 -- Successful pre-IND meeting for ITIL-306   GlobeNewswire Inc
Nov 8, 2021
08:06AM EST  Instil Bio, Inc. (Instil) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in two upcoming investor conferences in November:   GlobeNewswire Inc
Sep 20, 2021
09:41AM EDT  Clinicaltrials.gov Site Shows Instil Bio Study 'ITIL-168 in Advanced Melanoma Instil Bio' Recruiting   Benzinga
Sep 16, 2021
07:05AM EDT  Instil Bio Presents Subset Analysis Of Patients With Checkpoint-Refractory Advanced Melanoma From Compassionate Use Study At 2021 ESMO Congress   Benzinga
07:00AM EDT  Instil Bio Presents Subset Analysis of Patients with   GlobeNewswire Inc
Sep 13, 2021
07:04AM EDT  Instil Bio Receives IND Clearance To Initiate Phase 2 Clinical Trial For Patients With Advanced Melanoma   Benzinga
07:00AM EDT  Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma   GlobeNewswire Inc
Sep 2, 2021
07:00AM EDT  Instil Bio, Inc. (Instil) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in two upcoming investor conferences in September:   GlobeNewswire Inc
Aug 13, 2021
10:11AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 13, 2021   Benzinga
05:18AM EDT  Baird Initiates Coverage On Instil Bio with Outperform Rating, Announces Price Target of $34   Benzinga
Aug 12, 2021
07:23AM EDT  Instil Bio Q2 EPS $(0.27) Up From $(0.55) YoY   Benzinga
07:00AM EDT  - Presented compassionate use study in advanced melanoma demonstrating 67% of subjects achieved an objective response with 19% achieving a complete response   GlobeNewswire Inc
Jun 21, 2021
10:40AM EDT  IIROC Trading Resumption - TIL   PR Newswire
09:32AM EDT  IIROC Trading Halt - TIL   PR Newswire
Jun 1, 2021
07:00AM EDT  Instil Bio, Inc. (Instil) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at 9:30 a.m. ET.   GlobeNewswire Inc
May 26, 2021
08:17AM EDT  Morgan Stanley Maintains Equal-Weight on Instil Bio, Lowers Price Target to $23   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
07:11AM EDT  Instil Bio Q1 EPS $(0.66) Down From $(0.31) YoY   Benzinga
07:00AM EDT  Instil Bio Reports First Quarter 2021 Financial Results and   GlobeNewswire Inc
Apr 27, 2021
07:12AM EDT  Instil Bio Receives FDA Orphan Drug Designation For ITIL-168 in Melanoma   Benzinga
07:00AM EDT  Instil Bio, Inc. (Instil) (Nasdaq: TIL) received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of melanoma stages IIB to IV with its ITIL-168 TIL therapy.   GlobeNewswire Inc
Apr 23, 2021
07:28AM EDT  The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs   Benzinga
Apr 22, 2021
08:09AM EDT  The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs   Benzinga
Apr 16, 2021
08:01AM EDT  The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs   Benzinga
Apr 13, 2021
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2021   Benzinga
09:18AM EDT  Jefferies Initiates Coverage On Instil Bio with Buy Rating, Announces Price Target of $31   Benzinga
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
07:06AM EDT  Morgan Stanley Initiates Coverage On Instil Bio with Equal-Weight Rating, Announces Price Target of $24   Benzinga
07:05AM EDT  Cowen & Co. Initiates Coverage On Instil Bio with Outperform Rating   Benzinga
06:58AM EDT  Truist Securities Initiates Coverage On Instil Bio with Buy Rating, Announces Price Target of $32   Benzinga
Apr 12, 2021
07:19AM EDT  67% overall response rate and 19% complete response rate in 21 patients   GlobeNewswire Inc
Apr 10, 2021
09:19AM EDT  The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight   Benzinga
Mar 28, 2021
08:15AM EDT  The Past Week's Notable Insider Buys: Babcock & Wilcox, Designer Brands And More   Benzinga
Mar 26, 2021
07:28AM EDT  The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs   Benzinga
Mar 24, 2021
08:59AM EDT  The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping   Benzinga
Mar 23, 2021
05:00PM EDT  Instil Bio Announces Closing of Initial Public Offering and Full   GlobeNewswire Inc
08:18AM EDT  The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO   Benzinga
01:31AM EDT  AZN's COVID-19 Jab Shows 79% Efficacy, ZEAL Wins FDA   RTTNews
Mar 22, 2021
12:28PM EDT  The IPO Market Had A Busy Week   Benzinga
Mar 19, 2021
11:21AM EDT  Instil Bio Shares Open For Trade At $27; IPO Priced At $20/Share   Benzinga
09:28AM EDT  Instil Bio Shares Will Open For Quote At 10:10 a.m. EDT, Expected To Open For Trade After 10:20 a.m. EDT; IPO Priced At $20/Share   Benzinga
Mar 18, 2021
08:56PM EDT  Instil Bio Prices IPO Of 16 Mln Shares At $20.00/shr   RTTNews
08:27PM EDT  Instil Bio Announces Pricing of Upsized Initial Public Offering   GlobeNewswire Inc
09:01AM EDT  Instil Bio Now Sees 16M Share IPO Priced $19-$20 Per Share; Co. Previously Expected 13.9M Shares Priced $17-$19 Per Share   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC